Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ligand Avinza Once-Daily Dosing Will Be Core Promo Message For Elan Opioid

Executive Summary

Ligand will focus on Avinza once-daily dosing as the opioid's primary marketing message following the March 20 approval of the extended-release morphine drug licensed from Elan

You may also be interested in...



Chronic Pain Standard Proposed By FDA Too Strict, Four Trials OK, Cmte Says

Global chronic pain can be an appropriate Rx analgesic indication, but the revised clinical trial requirements under consideration by FDA may be too stringent, Arthritis Advisory Committee members said

From The Quarterly Conference Calls

Geneva Augmentin generic reserve: Geneva's generic amoxicillin/clavulanate earnings are being placed in a reserve in the event the company loses GlaxoSmithKline's appeal of the Augmentin patent lawsuit, Novartis CEO Daniel Vasella said July 22. "We will book sales, but we will not book the earnings out of this product but put them in a reserve," the exec said. "The additional exposure should we - against all odds - lose the appeal next year, would be an amount which we can digest, I would say, rather easily." GSK is appealing a May 22 ruling in Geneva's favor; a decision could come as early as January (1"The Pink Sheet" May 27, p. 20). Geneva launched amoxicillin generics in June...

Chronic Pain Standard Proposed By FDA Too Strict, Four Trials OK, Cmte Says

Global chronic pain can be an appropriate Rx analgesic indication, but the revised clinical trial requirements under consideration by FDA may be too stringent, Arthritis Advisory Committee members said

Related Content

UsernamePublicRestriction

Register

PS039545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel